查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1552540

美国女性医疗保健市场规模、份额、趋势分析报告：按应用、年龄、药物和细分市场预测，2024-2030

U.S. Women's Health Market Size, Share & Trends Analysis Report By Application (Contraceptives, Endometriosis & Uterine Fibroids), By Age (50 Years & Above, Others), By Drug (Prolia, XGEVA), And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 130 Pages | 商品交期: 2-10个工作天内

价格

美国女性医疗保健市场的成长与趋势：

Grand View Research, Inc.最新报告显示，到2030年，美国女性保健市场规模预计将达到296.8亿美元，2024年至2030年复合年增长率为4.04%。

目标疾病盛行率的上升是市场成长的主要驱动力。预计随着人口老化和肥胖的增加，骨关节炎的盛行率将会增加。导致女性荷尔蒙失调的主要因素包括饮食变化、压力和饮酒，这些都可能导致不孕。排卵障碍、多囊性卵巢症候群（PCOS）和子宫内膜异位症是不孕的主要原因。

增加对计划生育服务的公共资金进一步推动市场成长。据估计，美国每年约有 45% 的怀孕是意外怀孕。儘管避孕技术取得了进步，避孕药具的研发支出也有所增加，美国的意外怀孕率几十年来一直没有改变。这增加了低收入群体的经济负担，因为他们无法轻易获得现代、更有效的避孕方法。因此，联邦和州政府正在积极努力改善获得计划生育服务和现代避孕器的机会。例如，2019年，美国政府向联合国人口基金提供了6.08亿美元资金，用于计划生育和生殖健康发展。

此外，童婚在欠发达经济体和新兴经济体中最为常见，常导致早期意外怀孕。此外，避孕意识淡薄，使得问题更加严重。根据联合国儿童基金会的数据，过去十年童婚现象减少了 15%。然而，在美国，这个数字多年来并没有减少，因为美国一些州有法律允许18岁以下结婚。然而，该国正在努力解决童婚及其对妇女医疗保健的影响，包括倡导政策变革、促进女孩教育、提高对童婚负面影响及其对妇女健康影响的认识。支援服务。

此外，参与各种治疗药物开发和配製的主要公司都专注于合作研究和建立伙伴关係，以开发新药并保持市场竞争力。例如，2022年10月，Solera Health宣布推出全球首个女性健康网路数位点解决方案，解决女性健康问题的需求。此外，2022 年 11 月，Sebella Pharmaceuticals 宣布推出一个完全致力于女性医学的新部门。

美国女性医疗保健市场报告亮点

  • 从药物来看，Prolia 药物细分市场在 2023 年占据了最大的收益占有率，预计在预测期内将以最快的复合年增长率增长，因为它作为一种副作用很少的药物被广泛采用。
  • 从应用来看，由于人们对计划生育的认识不断提高，预计避孕药具领域在预测期内将呈现最快的复合年增长率。
  • 从年龄来看，到2023年，其他年龄层将主导美国女性用医药产业，因为子宫内膜异位症、荷尔蒙性不孕症和多囊性卵巢症候群等不孕问题在该年龄层中呈上升趋势。
  • 从分销管道来看，由于医院药房的女性用健康治疗产品库存充足且供应充足，医院药房细分市场将在 2023 年占据市场主导地位。
  • 领先的市场参与企业不断关注产品发布和地理扩张，以维持自己的地位。

目录

第一章调查方法和范围

第 2 章执行摘要

第 3 章美国女性医疗保健市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场推动要素分析
    • 市场限制因素分析
  • 美国女性保健市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析
    • 价格分析

第四章美国女性保健市场：按应用估算和趋势分析

  • 2023年及2030年市场占有率
  • 细分仪表板
  • 美国女性医疗保健市场前景：按应用分类
  • 2018-2030年市场规模、预测及趋势分析
    • 荷尔蒙不孕症
    • 避孕药
    • 停经后骨质疏鬆症
    • 子宫内膜异位症和子宫肌瘤
    • 闭经
    • 卵巢症候群（PCOS）

第五章美国女性保健品市场：依药品分类的预估及趋势分析

  • 2023年及2030年市场占有率
  • 细分仪表板
  • 美国女性医疗保健市场前景：按药物分类
  • 2018-2030年市场规模、预测及趋势分析

第六章美国女性保健市场：依年龄估计及趋势分析

  • 2023年及2030年市场占有率
  • 细分仪表板
  • 美国女性医疗保健市场前景：按年龄组别划分
  • 2018-2030年市场规模、预测及趋势分析

第七章 竞争格局

  • 主要市场参与企业的最新趋势和影响分析
  • 公司/竞争对手分类
  • 供应商情况
    • 主要经销商及通路伙伴名单
    • 主要客户
    • 2023年主要企业市场占有率分析
    • AbbVie, Inc.
    • Bayer AG
    • Merck &Co., Inc.
    • Pfizer, Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Agile Therapeutics
    • Amgen, Inc.
    • Apothecus Pharmaceutical Corp.
    • Eli Lilly and Company
    • Ferring BV
Product Code: GVR-4-68040-106-9

U.S. Women's Health Market Growth & Trends:

The U.S. women's health market size is expected to reach USD 29.68 billion by 2030, expanding at a CAGR of 4.04% from 2024 to 2030, according to a new report by Grand View Research, Inc. The rising prevalence of target diseases is a key driver for the growth of the market. With aging and the increasing prevalence of obesity, the prevalence of osteoarthritis is anticipated to grow. Some of the major factors responsible for hormonal imbalance in women include changes in dietary habits, stress, and consumption of alcohol, which can cause fertility issues. Ovulation problems, polycystic ovarian syndrome (PCOS), and endometriosis are major factors responsible for infertility.

The rise in public funding for family planning services is further driving the market growth. In the U.S., approximately 45% of pregnancies are estimated to be unwanted every year. Despite advancements in contraceptive technology and increased R&D spending on contraceptives, the rate of unplanned pregnancies in the U.S. has remained unchanged for decades. This has increased the economic burden on low-income families that do not have easy access to modern and more effective methods of contraception. Hence, federal & state governments are actively working toward improving family planning services and access to modern contraceptives. For instance, in 2019, the U.S. government provided USD 608 million in funding to UNFPA for family planning & reproductive health development.

Moreover, child marriages are most common in underdeveloped and developing economies, often leading to early and unplanned pregnancies. There is a lack of awareness about contraceptives, which amplifies the severity of the problem. According to UNICEF, child marriages decreased by 15% in the past decade. However, the number has not decreased over the years in the U.S. because laws in certain U.S. states allow marriages before 18 years. However, efforts to address child marriage and its impact on women's health are being undertaken in the country, which involve advocating for policy changes, promoting girls' education, raising awareness about the negative consequences of child marriage, and providing support services for affected girls and women.

Furthermore, key players involved in developing and formulating various therapeutics are focusing on collaborations and partnerships to develop novel drugs and maintain their competitive position in the market. For instance, in October 2022, Solera Health announced the launch of first-of-its-kind digital point solutions for women's Health networks to address women's health issues needs. Moreover, in November 2022, Sebela Pharmaceuticals announced the launch of a new division fully dedicated to women's health.

U.S. Women's Health Market Report Highlights:

  • Based on drug, the Prolia drug segment held the largest revenue share in 2023 and is anticipated to grow at the fastest CAGR over the forecast period owing to the wide adoption of the drug with very less side effects
  • Based on application, the contraceptives segment is expected to showcase the fastest CAGR over the forecast period, owing to an increase in awareness about family planning
  • Based on age, the others age segment dominated the U.S. women's health industry in 2023, due to the rising concerns of fertility, such as endometriosis, hormonal infertility, and PCOS in this age group
  • Based on distribution channel, the hospital pharmacy segment dominated the market in 2023 due to the high stock and availability of women's health therapeutics in the hospital pharmacies
  • Key market players are constantly focusing on product launches and geographical expansion to maintain their presence

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Application
    • 1.2.2. Age
    • 1.2.3. Drug
    • 1.2.4. Estimates and forecasts timeline.
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database.
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in U.S.
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Application outlook
    • 2.2.2. Age outlook
    • 2.2.3. Drug outlook.
  • 2.3. Competitive Insights

Chapter 3. U.S. Women's Health Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Rising incidence of target diseases
      • 3.2.1.2. Increasing initiatives by government and various organizations
      • 3.2.1.3. Rising publicly funded family planning services
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Patent expiry of major drugs
      • 3.2.2.2. Lawsuits related to products.
      • 3.2.2.3. Adverse effects associated with use of contraceptive drugs and devices.
  • 3.3. U.S. Women's Health Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape
    • 3.3.3. Pricing Analysis

Chapter 4. U.S. Women's Health Market: Application Estimates & Trend Analysis

  • 4.1. Application Market Share, 2023 & 2030
  • 4.2. Segment Dashboard
  • 4.3. U.S. Women's Health Market by Application Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.4.1. Hormonal infertility
      • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. Contraceptives
      • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3. Postmenopausal osteoporosis
      • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.4. Endometriosis & uterine fibroids
      • 4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.5. Menopause
      • 4.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.6. Polycystic ovary syndrome (PCOS)
      • 4.4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. U.S. Women's Health Market: Drug Estimates & Trend Analysis

  • 5.1. Drug Market Share, 2023 & 2030
  • 5.2. Segment Dashboard
  • 5.3. U.S. Women's Health Market by Drug Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 5.4.1. ACTONEL
      • 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2. YAZ, Yasmin, Yasminelle
      • 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.3. FORTEO
      • 5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.4. Minastrin 24 Fe
      • 5.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.5. Mirena
      • 5.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.6. NuvaRing
      • 5.4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.7. ORTHO TRI-CY LO
      • 5.4.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.8. Premarin
      • 5.4.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.9. Prolia
      • 5.4.9.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.10. Reclast/Aclasta
      • 5.4.10.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.11. XGEVA
      • 5.4.11.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.12. Zometa
      • 5.4.12.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.13. Others
      • 5.4.13.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. U.S. Women's Health Market: Age Estimates & Trend Analysis

  • 6.1. Age Market Share, 2023 & 2030
  • 6.2. Segment Dashboard
  • 6.3. U.S. Women's Health Market by Age Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 6.4.1. 50 years and above
      • 6.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.1.2. Postmenopausal osteoporosis
        • 6.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.1.3. Endometriosis & uterine fibroids
        • 6.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.1.4. Menopause
        • 6.4.1.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.1.5. Others
        • 6.4.1.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.2. Others
      • 6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company/Competition Categorization
  • 7.3. Vendor Landscape
    • 7.3.1. List of key distributors and channel partners
    • 7.3.2. Key customers
    • 7.3.3. Key company market share analysis, 2023
    • 7.3.4. AbbVie, Inc.
      • 7.3.4.1. Company overview
      • 7.3.4.2. Financial performance
      • 7.3.4.3. Product benchmarking
      • 7.3.4.4. Strategic initiatives
    • 7.3.5. Bayer AG
      • 7.3.5.1. Company overview
      • 7.3.5.2. Financial performance
      • 7.3.5.3. Product benchmarking
      • 7.3.5.4. Strategic initiatives
    • 7.3.6. Merck & Co., Inc.
      • 7.3.6.1. Company overview
      • 7.3.6.2. Financial performance
      • 7.3.6.3. Product benchmarking
      • 7.3.6.4. Strategic initiatives
    • 7.3.7. Pfizer, Inc.
      • 7.3.7.1. Company overview
      • 7.3.7.2. Financial performance
      • 7.3.7.3. Product benchmarking
      • 7.3.7.4. Strategic initiatives
    • 7.3.8. Teva Pharmaceutical Industries Ltd.
      • 7.3.8.1. Company overview
      • 7.3.8.2. Financial performance
      • 7.3.8.3. Product benchmarking
      • 7.3.8.4. Strategic initiatives
    • 7.3.9. Agile Therapeutics
      • 7.3.9.1. Company overview
      • 7.3.9.2. Financial performance
      • 7.3.9.3. Product benchmarking
      • 7.3.9.4. Strategic initiatives
    • 7.3.10. Amgen, Inc.
      • 7.3.10.1. Company overview
      • 7.3.10.2. Financial performance
      • 7.3.10.3. Product benchmarking
      • 7.3.10.4. Strategic initiatives
    • 7.3.11. Apothecus Pharmaceutical Corp.
      • 7.3.11.1. Company overview
      • 7.3.11.2. Financial performance
      • 7.3.11.3. Product benchmarking
      • 7.3.11.4. Strategic initiatives
    • 7.3.12. Eli Lilly and Company
      • 7.3.12.1. Company overview
      • 7.3.12.2. Financial performance
      • 7.3.12.3. Product benchmarking
      • 7.3.12.4. Strategic initiatives
    • 7.3.13. Ferring B.V.
      • 7.3.13.1. Company overview
      • 7.3.13.2. Financial performance
      • 7.3.13.3. Product benchmarking
      • 7.3.13.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 U.S. Women's Health Market, by application, 2018 - 2030 (USD Million)
  • Table 3 U.S. Women's Health Market, by drug, 2018 - 2030 (USD Million)
  • Table 4 U.S. Women's Health Market, by age, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in U.S.
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 U.S. Women's Health Market: market outlook
  • Fig. 10 Women's health competitive insights
  • Fig. 11 Parent market outlook
  • Fig. 12 Related/ancillary market outlook
  • Fig. 13 Penetration and growth prospect mapping
  • Fig. 14 Industry value chain analysis
  • Fig. 15 U.S. Women's Health Market driver impact
  • Fig. 16 U.S. Women's Health Market restraint impact
  • Fig. 17 U.S. Women's Health Market strategic initiatives analysis
  • Fig. 18 U.S. Women's Health Market: Application movement analysis
  • Fig. 19 U.S. Women's Health Market: Application outlook and key takeaways
  • Fig. 20 Hormonal infertility market estimates and forecast, 2018 - 2030
  • Fig. 21 Contraceptives estimates and forecast, 2018 - 2030
  • Fig. 22 Postmenopausal osteoporosis market estimates and forecast, 2018 - 2030
  • Fig. 23 Endometriosis & uterine fibroids estimates and forecast, 2018 - 2030
  • Fig. 24 Menopause market estimates and forecast, 2018 - 2030
  • Fig. 25 Polycystic ovary syndrome (PCOS) estimates and forecast, 2018 - 2030
  • Fig. 26 U.S. Women's Health Market: Drug movement analysis
  • Fig. 27 U.S. Women's Health Market: Drug outlook and key takeaways
  • Fig. 28 ACTONEL market estimates and forecast, 2018 - 2030
  • Fig. 29 YAZ, Yasmin, Yasminelle estimates and forecast, 2018 - 2030
  • Fig. 30 FORTEO market estimates and forecast, 2018 - 2030
  • Fig. 31 Minastrin 24 Fe estimates and forecast, 2018 - 2030
  • Fig. 32 Mirena market estimates and forecast, 2018 - 2030
  • Fig. 33 NuvaRing estimates and forecast, 2018 - 2030
  • Fig. 34 ORTHO TRI-CY LO market estimates and forecast, 2018 - 2030
  • Fig. 35 Premarin estimates and forecast, 2018 - 2030
  • Fig. 36 Prolia market estimates and forecast, 2018 - 2030
  • Fig. 37 Reclast/Aclasta estimates and forecast, 2018 - 2030
  • Fig. 38 XGEVA market estimates and forecast, 2018 - 2030
  • Fig. 39 Zometa estimates and forecast, 2018 - 2030
  • Fig. 40 Others estimates and forecast, 2018 - 2030
  • Fig. 41 U.S. Women's Health Market: Age movement Analysis
  • Fig. 42 U.S. Women's Health Market: Age outlook and key takeaways
  • Fig. 43 50 years and above market estimates and forecasts, 2018 - 2030
  • Fig. 44 Postmenopausal osteoporosis market estimates and forecasts,2018 - 2030
  • Fig. 45 Endometriosis & uterine fibroids market estimates and forecasts,2018 - 2030
  • Fig. 46 Menopause market estimates and forecasts,2018 - 2030
  • Fig. 47 Others market estimates and forecasts, 2018 - 2030
  • Fig. 48 Others market estimates and forecasts, 2018 - 2030
  • Fig. 49 Market share of key market players - U.S. Women's Health Market